Western Union Co vs State Street SPDR S&P Biotech ETF — how do they compare? Western Union Co trades at $8.9 (market cap $2.71B), while State Street SPDR S&P Biotech ETF trades at $154.43. The key difference: Western Union Co pays a 10.85% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Western Union Co nearer its low. Which is the better fit depends on your goals.
| WU | XBI | |
|---|---|---|
Market Cap | $2.71B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $10.28 | $164.28 |
52-Week Low | $7.04 | $85.16 |
Enterprise Value | $2.40B | — |
Dividend Yield | 10.85% | — |
Signals from Pluang's Aura AI — not financial advice
Western Union (WU) trades at $8.46, down 4.73% on the day, with a bullish technical signal but mixed sentiment. The stock shows attractive valuation metrics with a P/E of 6.37 and P/S of 0.69, supported by strong profitability including a 10.88% net margin and 47.66% ROE. Recent developments include a partnership with Total Wireless and pending acquisition of Intermex, while Q1 2026 earnings missed expectations. Cash flow trends show volatility, with 2025 net cash flow negative $469.2 million.
Outlook remains cautious due to declining revenue trends and mixed analyst ratings, with 58% hold recommendations. The 11% dividend yield offers income appeal, but competitive pressures and execution risks on digital transformation pose challenges. Near-term catalyst is Q2 2026 results on July 30, 2026, with consensus EPS estimate of $0.43.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →